BIOMAT Database Logo BIOMAT Database Logo

Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. 2013

Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Department of Internal Medicine.

UI MeSH Term Description Entries
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D053208 Kaplan-Meier Estimate A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995) Kaplan-Meier Survival Curve,Kaplan-Meier Analysis,Kaplan-Meier Survival Curves,Kaplan-Meier Test,Product-Limit Method,Analysis, Kaplan-Meier,Curve, Kaplan-Meier Survival,Curves, Kaplan-Meier Survival,Estimate, Kaplan-Meier,Kaplan Meier Analysis,Kaplan Meier Survival Curve,Kaplan Meier Survival Curves,Kaplan Meier Test,Method, Product-Limit,Methods, Product-Limit,Product Limit Method,Product-Limit Methods,Survival Curve, Kaplan-Meier,Survival Curves, Kaplan-Meier,Test, Kaplan-Meier
D019072 Antibiotic Prophylaxis Use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications. Antibiotic Premedication,Premedication, Antibiotic,Antibiotic Premedications,Premedications, Antibiotic,Prophylaxis, Antibiotic
D019259 Lamivudine A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2',3'-Dideoxy-3'-thiacytidine,2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-,3TC Lamivudine,Lamivudine, (+)-cis-,Lamivudine, (+-)-trans-,BCH-189,Epivir,GR-109714X,GR109714X,Lamivudine, (2S-cis)-Isomer,2',3' Dideoxy 3' thiacytidine,BCH 189,BCH189,GR 109714X,Lamivudine, 3TC

Related Publications

Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
June 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
April 2010, AIDS patient care and STDs,
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
February 1995, Lancet (London, England),
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Hepatitis B virus infection despite receiving lamivudine in one HIV-infected person.
January 2003, HIV clinical trials,
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.
February 2015, Antimicrobial agents and chemotherapy,
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
March 2010, AIDS (London, England),
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.
March 2013, AIDS (London, England),
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
January 2008, AIDS (London, England),
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
November 2007, Journal of medical virology,
Wang-Huei Sheng, and Yu-Chung Chuang, and Hsin-Yun Sun, and Mao-Song Tsai, and Sui-Yuan Chang, and Chien-Ching Hung, and Shan-Chwen Chang
Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy.
October 2002, Blood,
Copied contents to your clipboard!